Abstract
Background: The mortality rate of critically ill patients with coronavirus disease 2019 (COVID-19) was high. We aimed to assess the association between prolonged intermittent renal replacement therapy (PIRRT) and mortality in patients with COVID-19 undergoing invasive mechanical ventilation. Methods: This retrospective cohort study included all COVID-19 patients receiving invasive mechanical ventilation between February 12 and March 2, 2020. All patients were followed until death or March 28, and all survivors were followed for at least 30 days. Results: For 36 hospitalized COVID-19 patients receiving invasive mechanical ventilation, the mean age was 69.4 (±10.8) years, and 30 patients (83.3%) were men. Twenty-two (61.1%) patients received PIRRT (PIRRT group), and 14 cases (38.9%) were managed with conventional strategy (non-PIRRT group). There were no differences in age, sex, comorbidities, complications, treatments, and most of the laboratory findings. During the median follow-up period of 9.5 (interquartile range 4.3–33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11 of 14 (78.6%) patients in the non-PIRRT group died. Kaplan-Meier analysis demonstrated prolonged survival in patients in the PIRRT group compared with that in the non-PIRRT group (p = 0.042). The association between PIRRT and a reduced risk of mortality remained significant in 3 different models, with adjusted hazard ratios varying from 0.332 to 0.398. Increased IL-2 receptor, TNF-α, procalcitonin, prothrombin time, and NT-proBNP levels were significantly associated with an increased risk of mortality in patients with PIRRT. Conclusion: PIRRT may be beneficial for the treatment of COVID-19 patients with invasive mechanical ventilation. Further prospective multicenter studies with larger sample sizes are required.
References
1.
Zhu
N
, Zhang
D
, Wang
W
, Li
X
, Yang
B
, Song
J
, et al. A novel coronavirus from patients with pneumonia in China, 2019
. N Engl J Med
. 2020
;382
(8
):727
–33
. .2.
Yang
X
, Yu
Y
, Xu
J
, Shu
H
, Xia
J
, Liu
H
, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
. Lancet Respir Med
. 2020 May
;8
(5
):475
–81
.3.
Zarbock
A
, Gomez
H
, Kellum
JA
. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies
. Curr Opin Crit Care
. 2014
;20
(6
):588
–95
. .4.
Vincent
JL
. Fluid management in the critically ill
. Kidney Int
. 2019
;96
(1
):52
–7
. .5.
Xie
J
, Wang
H
, Kang
Y
, Zhou
L
, Liu
Z
, Qin
B
, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey
. Crit Care Med
. 2020
;48
(3
):e209
–18
. .6.
Huang
C
, Wang
Y
, Li
X
, Ren
L
, Zhao
J
, Hu
Y
, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
. Lancet
. 2020
;395
(10223
):497
–506
.7.
Qin
C
, Zhou
L
, Hu
Z
, Zhang
S
, Yang
S
, Tao
Y
, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China
. Clin Infect Dis
. 2020 Jul 28
;71
(15
):762
–8
.8.
Ruan
Q
, Yang
K
, Wang
W
, Jiang
L
, Song
J
. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
. Intensive Care Med
. 2020 May
;46
(5
):846
–8
.9.
Guan
W-J
, Ni
Z-Y
, Hu
Y
, Liang
W-H
, Ou
C-Q
, He
J-X
, et al. Clinical characteristics of coronavirus disease 2019 in China
. New Engl J Med
. 2020 Apr 30
;382
(18
):1708
–20
.10.
Wong
CK
, Lam
CW
, Wu
AK
, Ip
WK
, Lee
NL
, Chan
IH
, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
. Clin Exp Immunol
. 2004
;136
(1
):95
–103
. .11.
Mahallawi
WH
, Khabour
OF
, Zhang
Q
, Makhdoum
HM
, Suliman
BA
. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
. Cytokine
. 2018
;104
:8
–13
. .12.
Forni
LG
, Joannidis
M
. IDEAL timing of renal replacement therapy in critical care
. Nat Rev Nephrol
. 2019
;15
(1
):5
–6
. .13.
Wolf
T
, Kann
G
, Becker
S
, Stephan
C
, Brodt
HR
, de Leuw
P
, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care
. Lancet
. 2015
;385
(9976
):1428
–35
. .14.
Rewa
OG
, Villeneuve
PM
, Lachance
P
, Eurich
DT
, Stelfox
HT
, Gibney
RTN
, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review
. Intensive Care Med
. 2017
;43
(6
):750
–63
. .15.
Alfaraj
SH
, Al-Tawfiq
JA
, Assiri
AY
, Alzahrani
NA
, Alanazi
AA
, Memish
ZA
. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study
. Travel Med Infect Dis
. 2019 May–Jun
;29
:48
–50
. .16.
Karkar
A
, Ronco
C
. Prescription of CRRT: a pathway to optimize therapy
. Ann Intensive Care
. 2020
;10
(1
):32
. .17.
Miao
H
, Shi
J
, Wang
C
, Lu
G
, Zhu
X
, Wang
Y
, et al. Continuous renal replacement therapy in pediatric severe sepsis: a propensity score-matched prospective multicenter cohort study in the PICU
. Crit Care Med
. 2019
;47
(10
):e806
–13
. .18.
Putzu
A
, Fang
MX
, Boscolo Berto
M
, Belletti
A
, Cabrini
L
, Cassina
T
, et al. Blood purification with continuous veno-venous hemofiltration in patients with sepsis or ARDS: a systematic review and meta-analysis
. Minerva Anestesiol
. 2017
;83
(8
):867
–77
. .19.
Fayad
AII
, Buamscha
DG
, Ciapponi
A
. Timing of renal replacement therapy initiation for acute kidney injury
. Cochrane Database Syst Rev
. 2018
;12
:CD010612
. .20.
Fayad
AI
, Buamscha
DG
, Ciapponi
A
. Intensity of continuous renal replacement therapy for acute kidney injury
. Cochrane Database Syst Rev
. 2016
;10
:CD010613
. .21.
Allegretti
AS
, Endres
P
, Parris
T
, Zhao
S
, May
M
, Sylvia-Reardon
M
, et al. Accelerated venovenous hemofiltration as a transitional renal replacement therapy in the intensive care unit
. Am J Nephrol
. 2020
;51
(4
):318
–26
. .22.
Sethi
SK
, Mittal
A
, Nair
N
, Bagga
A
, Iyenger
A
, Ali
U
, et al. Pediatric Continuous Renal Replacement Therapy (PCRRT) expert committee recommendation on prescribing prolonged intermittent renal replacement therapy (PIRRT) in critically ill children
. Hemodial Int
. 2020 Apr
;24
(2
):237
–51
.23.
China NHCo
. The new coronavirus pneumonia prevention and control program
. 5th ed. China
; 2020
.24.
Yang
Y
, Shi
J
, Ge
S
, Guo
S
, Xing
X
, Wang
Y
, et al. Association between prolonged intermittent renal replacement therapy and all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study
. medRxiv
. 2020 July
. .25.
Chousterman
BG
, Swirski
FK
, Weber
GF
. Cytokine storm and sepsis disease pathogenesis
. Semin Immunopathol
. 2017
;39
(5
):517
–28
. .26.
Giamarellos-Bourboulis
EJ
. Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach
. Immunotherapy
. 2013
;5
(3
):207
–9
. .27.
Chen
S
, Liu
G
, Chen
J
, Hu
A
, Zhang
L
, Sun
W
, et al. Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm
. Front Immunol
. 2019
;10
:1393
. .28.
Kennedy
JR
. Phosphatidylserine’s role in Ebola’s inflammatory cytokine storm and hemorrhagic consumptive coagulopathy and the therapeutic potential of annexin V
. Med Hypotheses
. 2020
;135
:109462
. .29.
Lau
SK
, Lau
CC
, Chan
KH
, Li
CP
, Chen
H
, Jin
DY
, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
. J Gen Virol
. 2013
;94
(Pt 12
):2679
–90
. .30.
Li
Y
, Chen
M
, Cao
H
, Zhu
Y
, Zheng
J
, Zhou
H
. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
. Microbes Infect
. 2013
;15
(2
):88
–95
. .31.
Kannan
S
, Shaik Syed Ali
P
, Sheeza
A
, Hemalatha
K
. COVID-19 (novel coronavirus 2019): recent trends
. Eur Rev Med Pharmacol Sci
. 2020
;24
(4
):2006
–11
.32.
Hoffmann
M
, Kleine-Weber
H
, Schroeder
S
, Kruger
N
, Herrler
T
, Erichsen
S
, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
. Cell
. 2020 Apr 16
;181
(2
):271
–80.e8
.33.
Hamming
I
, Timens
W
, Bulthuis
ML
, Lely
AT
, Navis
G
, van Goor
H
. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
. J Pathol
. 2004
;203
(2
):631
–7
. .34.
Santos
RAS
, Sampaio
WO
, Alzamora
AC
, Motta-Santos
D
, Alenina
N
, Bader
M
, et al. The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7)
. Physiol Rev
. 2018
;98
(1
):505
–53
.35.
Sun
ML
, Yang
JM
, Sun
YP
, Su
GH
. [Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia]
. Zhonghua Jie He He Hu Xi Za Zhi
. 2020
;43
(0
):E014
. .36.
Tetro
JA
. Is COVID-19 receiving ADE from other coronaviruses?
Microbes Infect
. 2020 Mar
;22
(2
):72
–3
.37.
Bar-Or
D
, Carrick
MM
, Mains
CW
, Rael
LT
, Slone
D
, Brody
EN
. Sepsis, oxidative stress, and hypoxia: are there clues to better treatment?
Redox Rep
. 2015
;20
(5
):193
–7
. .38.
Chakraborty
RK
, Burns
B
. Systemic inflammatory response syndrome
. Treasure Island, FL
: StatPearls
; 2020
.39.
Joannidis
M
, Forni
LG
. Clinical review: timing of renal replacement therapy
. Crit Care
. 2011
;15
(3
):223
. .40.
Matsuda
K
, Moriguchi
T
, Oda
S
, Hirasawa
H
. Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome
. Contrib Nephrol
. 2010
;166
:83
–92
. .41.
Elbahlawan
L
, West
NK
, Avent
Y
, Cheng
C
, Liu
W
, Barfield
RC
, et al. Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic stem cell transplantation
. Pediatr Blood Cancer
. 2010
;55
(3
):540
–5
. .42.
Han
F
, Sun
R
, Ni
Y
, Hu
X
, Chen
X
, Jiang
L
, et al. Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome
. Am J Med Sci
. 2015
;349
(3
):199
–205
. .43.
DiCarlo
JV
, Alexander
SR
, Agarwal
R
, Schiffman
JD
. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy
. J Pediatr Hematol Oncol
. 2003
;25
(10
):801
–5
. .44.
Edrees
F
, Li
T
, Vijayan
A
. Prolonged intermittent renal replacement therapy
. Adv Chronic Kidney Dis
. 2016
;23
(3
):195
–202
. .45.
Fathima
N
, Kashif
T
, Janapala
RN
, Jayaraj
JS
, Qaseem
A
. Single-best choice between intermittent versus continuous renal replacement therapy: a review
. Cureus
. 2019
;11
(9
):e5558
. .46.
Ha
SO
, Kim
HS
, Park
S
, Jung
KS
, Jang
SH
, Han
SJ
, et al. Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy
. Springerplus
. 2016
;5
(1
):1909
. .47.
Cha
RH
, Joh
JS
, Jeong
I
, Lee
JY
, Shin
HS
, Kim
G
, et al. Renal complications and their prognosis in Korean patients with middle east respiratory syndrome-coronavirus from the central MERS-CoV designated hospital
. J Korean Med Sci
. 2015
;30
(12
):1807
–14
. .48.
Yang
X
, Yu
Y
, Xu
J
, Shu
H
, Xia
J
, Liu
H
, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
. Lancet Respir Med
. 2020 May
;8
(5
):475
–81
.© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
